Immunomedics Inc. secured patent coverage for its IMMU-140 cancer treatment in the U.S.
The protection will last until July 2033 and will cover the use of IMMU-140 in multiple cancer types, including melanoma, kidney or liver.
IMMU-140 is an investigational drug that is currently under development.